California State Teachers Retirement System raised its holdings in Celldex Therapeutics, Inc. (NASDA

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Conse

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector

Celldex Therapeutics (NASDAQ: CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did n

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and

Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fa

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial eval

Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not

Celldex Therapeutics said on Tuesday it would discontinue the ​development of its experimental drug

HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline result

Guggenheim analyst Yatin Suneja maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raise

Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Off

HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Mart

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentat

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive resu

-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster

Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Conse

HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial resul

Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depleti

The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While

Celldex Therapeutics (NASDAQ: CLDX) executives used an appearance at H.C. Wainwright's annual Inflam

HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that managem

Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials

Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew m

  During the session on Thursday, 461 stocks hit new 52-week lows.

  During Tuesday's session, 275 companies made new 52-week lows.

  During Monday's trading, 1214 companies set new 52-week lows.

  On Friday, 422 stocks made new 52-week lows.

  During the Thursday's session, 100 stocks hit new 52-week lows.

  On Wednesday, 73 stocks hit new 52-week lows.

  Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to repo

    During Tuesday's morning session, 95 companies made new 52-week highs.

    On Thursday morning, 159 companies achieved new highs for the year.

    Before 10 a.m. ET on Tuesday, 128 companies hit new 52-week highs.

  This morning 161 companies reached new 52-week highs.

    Tuesday's morning session saw 105 companies set new 52-week highs.

    This morning 143 companies set new 52-week highs.

    Before 10 a.m. ET on Tuesday, 165 companies set new 52-week highs.

    During Monday's morning trading, 285 companies set new 52-week highs.

    Friday morning saw 331 companies set new 52-week highs.

    This morning 194 companies reached new 52-week highs.

    Monday morning saw 558 companies set new 52-week highs.

  This morning 230 companies reached new 52-week highs.

  On Monday morning, 204 companies hit new 52-week highs.